NASDAQ:CELG - Celgene Stock Price, Price Target & More

$89.4850 +0.53 (+0.60 %)

(As of 04/23/2018 04:00 PM ET)

Previous Close$89.4850

Today's Range$88.71 - $90.03

52-Week Range$84.25 - $147.17

Volume3.40 million shs

Average Volume7.63 million shs

Market Capitalization$66.91 billion

P/E Ratio13.08

Dividend YieldN/A

Beta1.48

About Celgene (NASDAQ:CELG)

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; and Prothena Corporation plc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:CELG

CUSIP15102010

Webwww.celgene.com

Phone908-673-9000

Debt

Debt-to-Equity Ratio2.29%

Current Ratio4.99%

Quick Ratio4.80%

Price-To-Earnings

Trailing P/E Ratio13.08

Forward P/E Ratio11.64

P/E Growth0.59

Sales & Book Value

Annual Sales$13.00 billion

Price / Sales5.18

Cash Flow$7.6680 per share

Price / Cash11.67

Book Value$8.79 per share

Price / Book10.18

Profitability

EPS (Most Recent Fiscal Year)$6.84

Net Income$2.94 billion

Net Margins22.38%

Return on Equity67.50%

Return on Assets18.33%

Miscellaneous

Employees7,467

Outstanding Shares752,180,000

How to Become a New Pot Stock Millionaire

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene's stock split on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were distributed to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene declared that its board has initiated a share buyback plan on Wednesday, February 14th 2018, which authorizes the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company's board believes its stock is undervalued.

How were Celgene's earnings last quarter?

Celgene (NASDAQ:CELG) posted its earnings results on Thursday, January, 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.78 by $0.09. The biopharmaceutical company earned $3.48 billion during the quarter, compared to analyst estimates of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm's revenue was up 16.9% compared to the same quarter last year. During the same quarter last year, the company posted $1.61 earnings per share. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Friday, May, 4th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene updated its FY18 earnings guidance on Thursday, January, 25th. The company provided earnings per share (EPS) guidance of $8.70-8.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.65. The company issued revenue guidance of $14.4-14.8 billion, compared to the consensus revenue estimate of $14.77 billion.

What price target have analysts set for CELG?

31 brokers have issued 12-month target prices for Celgene's stock. Their forecasts range from $85.00 to $166.00. On average, they expect Celgene's stock price to reach $126.4536 in the next twelve months. View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:

1. According to Zacks Investment Research, "Celgene was on the look-out of new deals and acquisitions given a lacklustre 2017. The company recently acquired Juno Therapeutics and added JCAR017 (lisocabtagene maraleucel; liso-cel) to Celgene’s lymphoma pipeline. JCAR017 is a best-in-class CD19-directed CAR-T candidate, currently in a pivotal program for relapsed and/or refractory diffuse large B-cell lymphoma. The candidate is expected to obtain regulatory approval in the United States in 2019 and generate sales of approximately $3 billion. The bluebird deal will further bolster Celgene’s presence in the CAR-T space. Things have been on the downturn for the company since last October after a series of pipeline failures. A late stage study on its lead cancer drug Revlimid in combination with Rituxan failed. Celgene suffered yet another setback when it received Refusal to File letter from the FDA regarding its New Drug Application for multiple sclerosis candidate ozanimod." (4/19/2018)
2. Cann analysts commented, "Celgene announced today that John Weiland has been elected to its board of directors. Mr. Weiland was most recently President and Chief Operating Officer of C.R. Bard, Inc. Prior to this role, Mr. Weiland held the position of Group President of Bard and had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide Manufacturing Operations. We believe Mr. Weiland will bring significant commercial and operational experience to the Celgene Board." (2/15/2018)
3. Cantor Fitzgerald analysts commented, "CELG’s current CEO, Mark Alles, will assume the role of Chairman of the Board, following the retirement of current COB Robert Hugin, effective February 5th, which follows his departure as President in early 2016." (1/29/2018)

Who are some of Celgene's key competitors?

Some companies that are related to Celgene include Novo Nordisk (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN) and Astellas Pharma (ALPMY).

Who are Celgene's key executives?

Celgene's management team includes the folowing people:

Mr. Mark J. Alles, Chairman & CEO (Age 59)
Mr. Peter N. Kellogg BSE, MBA, Exec. VP, CFO & Chief Accounting Officer (Age 62)
Mr. Rupert J. Vessey, Exec. VP and Pres of Research & Early Devel. (Age 53)
Mr. Patrick E. Flanigan III, Corp. VP of Investor Relations
Mr. Gerald F. Masoudi, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50)

Has Celgene been receiving favorable news coverage?

Media stories about CELG stock have been trending somewhat negative this week, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celgene earned a media sentiment score of -0.06 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 44.77 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $89.4850.

How big of a company is Celgene?

Celgene has a market capitalization of $66.91 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]

MarketBeat Community Rating for Celgene (CELG)

Community Ranking:		3.8 out of 5 ( )
Outperform Votes:		1,739 (Vote Outperform)
Underperform Votes:		548 (Vote Underperform)
Total Votes:		2,287

MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Celgene (NASDAQ:CELG) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

31 Wall Street analysts have issued ratings and price targets for Celgene in the last 12 months. Their average twelve-month price target is $126.4536, suggesting that the stock has a possible upside of 41.31%. The high price target for CELG is $166.00 and the low price target for CELG is $85.00. There are currently 1 sell rating, 12 hold ratings, 17 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.58	2.58	2.58	2.67
Ratings Breakdown:	1 Sell Rating(s) 12 Hold Rating(s) 17 Buy Rating(s) 1 Strong Buy Rating(s)	1 Sell Rating(s) 12 Hold Rating(s) 17 Buy Rating(s) 1 Strong Buy Rating(s)	1 Sell Rating(s) 12 Hold Rating(s) 17 Buy Rating(s) 1 Strong Buy Rating(s)	2 Sell Rating(s) 6 Hold Rating(s) 22 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$126.4536	$127.3464	$129.7750	$148.9115
Price Target Upside:	41.31% upside	44.27% upside	26.11% upside	21.69% upside

Celgene (NASDAQ:CELG) Consensus Price Target History

Price Target History for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/17/2018	Credit Suisse Group	Set Price Target	Buy	$129.00	Low
4/13/2018	Morgan Stanley	Reiterated Rating	Equal -> Equal Weight	$93.00	Low
4/2/2018	Cantor Fitzgerald	Set Price Target	Hold	$112.00	Low
3/28/2018	Leerink Swann	Set Price Target	Buy	$123.00	High
3/26/2018	Goldman Sachs	Lower Price Target	Sell -> Sell	$97.00 -> $85.00	Low
3/21/2018	JPMorgan Chase	Initiated Coverage	Overweight -> Overweight	$110.00	Low
3/1/2018	Robert W. Baird	Reiterated Rating	Hold	$92.00	Medium
2/28/2018	BMO Capital Markets	Lower Price Target	Outperform -> Outperform	$144.00 -> $139.00	High
2/28/2018	William Blair	Reiterated Rating	Buy		High
2/28/2018	UBS	Set Price Target	Buy	$106.00	High
2/28/2018	Stifel Nicolaus	Reiterated Rating	Buy -> Buy	$130.00 -> $128.00	High
2/28/2018	SunTrust Banks	Downgrade	Buy -> Hold	$139.00 -> $106.00	High
2/15/2018	Cann	Reiterated Rating	Buy	$163.00	Low
2/13/2018	Barclays	Upgrade	Equal Weight -> Overweight	$91.51 -> $105.00	Low
2/4/2018	Mizuho	Reiterated Rating	Buy	$128.00	High
1/23/2018	Royal Bank of Canada	Reiterated Rating	Top Pick		Low
1/23/2018	BTIG Research	Reiterated Rating	Hold		Medium
1/18/2018	Piper Jaffray	Reiterated Rating	Hold	$104.00	Low
1/10/2018	Guggenheim	Reiterated Rating	Buy	$147.00	Low
1/8/2018	Deutsche Bank	Set Price Target	Hold	$110.00	Low
1/8/2018	Oppenheimer	Set Price Target	Buy	$166.00	High
1/5/2018	Bank of America	Downgrade	Buy -> Neutral	$104.68 -> $120.00	Medium
12/27/2017	Sanford C. Bernstein	Downgrade	Outperform -> Market Perform	$121.00	High
12/22/2017	Citigroup	Reiterated Rating	Hold		Medium
12/8/2017	Atlantic Securities	Upgrade	Neutral -> Overweight		High
11/16/2017	Canaccord Genuity	Set Price Target	Buy	$140.00	N/A
10/27/2017	JMP Securities	Downgrade	Outperform -> Market Perform		N/A
10/26/2017	Wells Fargo	Downgrade	Outperform -> Market Perform		N/A
10/16/2017	Jefferies Group	Reiterated Rating	Buy	$160.00	N/A
9/12/2017	Cowen	Reiterated Rating	Buy	$150.00	Low
7/31/2017	Argus	Upgrade	Hold -> Buy	$96.93 -> $160.00	Low
1/8/2017	Evercore ISI	Reiterated Rating	Buy	$135.00	N/A
11/9/2016	Standpoint Research	Downgrade	Buy -> Hold		N/A
4/28/2016	Raymond James	Reiterated Rating	Buy		N/A

(Data available from 4/23/2016 forward)

Celgene (NASDAQ:CELG) Earnings History and Estimates Chart

Earnings by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Earnings Estimates

2018 EPS Consensus Estimate: $7.73

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$1.77	$1.77	$1.77
Q2 2018	1	$1.88	$1.88	$1.88
Q3 2018	1	$2.00	$2.00	$2.00
Q4 2018	2	$2.08	$2.08	$2.08

Celgene (NASDAQ CELG) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/4/2018		$1.78					N/A
4/25/2018		$1.96					N/A
1/25/2018	Q4 2017	$1.78	$1.87	$3.4645 billion	$3.4830 billion	View	Listen
10/26/2017	Q3 2017	$1.87	$1.91	$3.4167 billion	$3.2870 billion	View	N/A
7/27/2017	6/30/2017	$1.61	$1.82	$3.2324 billion	$3.2680 billion	View	N/A
4/27/2017	Q1 2017	$1.47	$1.68	$3.0367 billion	$2.96 billion	View	N/A
1/26/2017	Q416	$1.59	$1.61	$3.03 billion	$2.98 billion	View	N/A
10/27/2016	Q316	$1.31	$1.58	$2.84 billion	$2.9830 billion	View	Listen
7/28/2016	Q216	$1.39	$1.44	$2.70 billion	$2.74 billion	View	Listen
4/28/2016	Q116	$1.29	$1.32	$2.59 billion	$2.51 billion	View	Listen
1/28/2016	Q415	$1.22	$1.18	$2.54 billion	$2.54 billion	View	Listen
11/5/2015	Q315	$1.09	$1.23	$2.40 billion	$2.33 billion	View	N/A
7/23/2015	Q215	$1.08	$1.23	$2.24 billion	$2.28 billion	View	Listen
4/30/2015	Q115	$0.93	$0.95	$2.11 billion	$2.08 billion	View	N/A
1/29/2015	Q414	$0.88	$0.91	$2.08 billion	$2.09 billion	View	N/A
10/23/2014	Q314	$0.82	$0.97	$1.96 billion	$1.96 billion	View	Listen
7/24/2014	Q214	$0.77	$0.80	$1.85 billion	$1.87 billion	View	N/A
4/24/2014	Q114	$1.65	$1.67	$1.77 billion	$1.71 billion	View	N/A
1/30/2014	Q413	$1.54	$1.51	$1.72 billion	$1.76 billion	View	Listen
10/24/2013	Q313	$1.54	$1.56	$1.64 billion	$1.67 billion	View	N/A
7/25/2013	Q2 2013	$1.44	$1.52	$1.54 billion	$1.56 billion	View	Listen
4/25/2013	Q1 2013	$1.35	$1.37	$1.47 billion	$1.43 billion	View	Listen
1/24/2013	Q4 2012	$1.31	$1.32	$1.45 billion	$1.42 billion	View	Listen
10/25/2012		$1.26	$1.29			View	N/A
7/26/2012		$1.19	$1.22			View	N/A
4/26/2012		$1.13	$1.08			View	N/A
1/26/2012		$1.06	$1.05			View	N/A
10/27/2011		$0.95	$1.02			View	N/A
7/28/2011		$0.85	$0.89			View	N/A
4/28/2011		$0.80	$0.83			View	N/A
1/27/2011		$0.73	$0.73			View	N/A
10/28/2010	Q3 2010	$0.32	$0.32			View	N/A
7/29/2010	Q2 2010	$0.30	$0.30			View	N/A
4/29/2010	Q1 2010	$0.28	$0.27			View	N/A
1/28/2010	Q4 2009	$0.29	$0.29			View	N/A
10/22/2009	Q3 2009	$0.25	$0.25			View	N/A
7/23/2009	Q2 2009	$0.21	$0.20			View	N/A
4/30/2009	Q1 2009	$0.20	$0.16			View	N/A
1/29/2009	Q4 2008	$0.19	$0.19			View	N/A
10/23/2008	Q3 2008	$0.18	$0.17			View	N/A
7/24/2008	Q2 2008	$0.16	$0.15			View	N/A
5/8/2008	Q1 2008	$0.16	$0.17			View	N/A
1/31/2008	Q4 2007	$0.15	$0.15			View	N/A

(Earnings results data provided by Zacks Investment Research)

Celgene (NASDAQ:CELG) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Celgene (NASDAQ CELG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 78.53%

Insider Trading History for Celgene (NASDAQ:CELG)

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2018	James J Loughlin	Director	Sell	9,250	$92.01	$851,092.50
2/23/2018	Ernest Mario	Director	Sell	13,370	$94.49	$1,263,331.30
2/20/2018	Gilla Kaplan	Director	Sell	9,250	$94.83	$877,177.50	94,801
2/15/2018	Gilla Kaplan	Director	Sell	9,250	$95.99	$887,907.50	94,801
2/8/2018	Mark J Alles	Insider	Buy	3,260	$91.90	$299,594.00	178,904
9/25/2017	Terrie Curran	Insider	Sell	1,727	$143.89	$248,498.03	3,925
9/12/2017	Gilla Kaplan	Director	Sell	9,250	$141.56	$1,309,430.00	85,551
9/5/2017	Michael D Casey	Director	Sell	9,250	$139.03	$1,286,027.50	9,250
8/10/2017	Ernest Mario	Director	Sell	18,506	$130.52	$2,415,403.12	69,424
8/2/2017	Gilla Kaplan	Director	Sell	7,500	$134.52	$1,008,900.00	76,301
6/26/2017	James J Loughlin	Director	Sell	18,500	$133.57	$2,471,045.00	32,877
6/22/2017	Michael A Friedman	Director	Sell	10,000	$132.50	$1,325,000.00	5,000
6/22/2017	Robert J Hugin	Insider	Sell	175,970	$134.14	$23,604,615.80	1,033,909
6/21/2017	Michael D Casey	Director	Sell	9,250	$133.05	$1,230,712.50	9,250
6/19/2017	Michael D. Casey	Director	Sell	9,250	$125.59	$1,161,707.50
6/15/2017	Rupert Vessey	Insider	Sell	4,785	$120.18	$575,061.30	4,004
5/1/2017	James J Loughlin	Director	Sell	9,250	$124.00	$1,147,000.00	32,169
3/30/2017	Gilla Kaplan	Director	Sell	14,033	$123.83	$1,737,706.39	73,109
3/1/2017	Rupert Vessey	Insider	Sell	4,000	$124.42	$497,680.00	778
11/9/2016	Michael A Friedman	Director	Sell	18,600	$116.10	$2,159,460.00	18,600
10/24/2016	Corp /De/ Celgene	Major Shareholder	Buy	800,150	$14.00	$11,202,100.00
10/3/2016	Michael A Friedman	Director	Sell	56,116	$103.66	$5,816,984.56	50,000
9/23/2016	Richard W Barker	Director	Sell	20,000	$110.82	$2,216,400.00	31,332
9/15/2016	Gilla Kaplan	Director	Sell	9,710	$106.44	$1,033,532.40	72,142
8/23/2016	James J Loughlin	Director	Sell	27,500	$114.10	$3,137,750.00	42,919
8/22/2016	Michael D Casey	Director	Sell	43,134	$114.01	$4,917,707.34
7/28/2016	Robert J Hugin	Insider	Sell	100,000	$110.00	$11,000,000.00	1,022,201
6/20/2016	Robert J Hugin	Insider	Sell	75,000	$100.16	$7,512,000.00	1,122,201
4/4/2016	Gilla Kaplan	Director	Sell	15,967	$101.84	$1,626,079.28	72,518
3/3/2016	Michael W Bonney	Director	Buy	2,000	$103.01	$206,020.00
2/22/2016	James J Loughlin	Director	Sell	2,100	$104.12	$218,652.00	19,785
12/28/2015	Ernest Mario	Director	Sell	40,000	$119.36	$4,774,400.00	82,449
12/23/2015	Michael D Casey	Director	Sell	20,000	$122.11	$2,442,200.00
12/21/2015	Gilla Kaplan	Director	Sell	14,464	$110.62	$1,600,007.68	88,485
9/10/2015	Gilla Kaplan	Director	Sell	15,000	$122.45	$1,836,750.00	88,485
9/8/2015	Michael D. Casey	Director	Sell	15,000	$121.76	$1,826,400.00
7/13/2015	Thomas O Daniel	Insider	Sell	30,156	$120.78	$3,642,241.68
6/10/2015	Gilla Kaplan	Director	Sell	15,000	$111.74	$1,676,100.00
6/9/2015	Michael D Casey	Director	Sell	15,000	$111.18	$1,667,700.00
2/26/2015	Gilla Kaplan	Director	Sell	15,000	$122.89	$1,843,350.00
2/6/2015	Mark J Alles	Insider	Sell	117,099	$120.68	$14,131,507.32
1/15/2015	Lawrence V Stein	Insider	Sell	26,666	$120.01	$3,200,186.66
1/2/2015	Gilla Kaplan	Director	Sell	45,536	$113.47	$5,166,969.92
12/8/2014	Gilla Kaplan	Director	Sell	15,000	$118.20	$1,773,000.00
11/3/2014	Robert J Hugin	Insider	Sell	158,000	$106.68	$16,855,440.00
10/27/2014	Ernest Mario	Director	Sell	100,000	$102.85	$10,285,000.00
10/24/2014	Michael D Casey	Director	Sell	15,000	$102.94	$1,544,100.00
9/8/2014	Gilla Kaplan	Director	Sell	30,000	$93.73	$2,811,900.00
8/4/2014	Perry A Karsen	Insider	Sell	39,104	$87.55	$3,423,555.20
7/25/2014	Richard W Barker	Director	Sell	17,600	$87.03	$1,531,728.00
5/1/2014	Perry Karsen	Insider	Sell	11,922	$146.78	$1,749,911.16	25,705
3/4/2014	Michael Casey	Director	Sell	12,770	$162.33	$2,072,954.10
2/5/2014	Ernest Mario	Director	Sell	13,500	$151.87	$2,050,245.00	100,671
12/23/2013	Lawrence Stein	Insider	Sell	12,062	$168.19	$2,028,707.78	50
10/25/2013	Carrie Smith Cox	Director	Sell	18,750	$157.67	$2,956,312.50
9/4/2013	Gilla Kaplan	Director	Sell	15,000	$143.92	$2,158,800.00	22,688
8/28/2013	Thomas Daniel	Insider	Sell	32,263	$137.06	$4,421,966.78	15,349
8/2/2013	Perry A Karsen	Insider	Sell	93,008	$146.50	$13,625,672.00
5/30/2013	Robert J Hugin	Insider	Sell	68,087	$123.58	$8,414,191.46
5/29/2013	Ernest Mario	Director	Buy	1,000	$123.72	$123,720.00
5/28/2013	Thomas O Daniel	Insider	Sell	32,959	$124.91	$4,116,908.69

(Data available from 1/1/2013 forward)

Celgene (NASDAQ CELG) News Headlines

Source:

Date	Headline
	Celgene: Bold Pursuits In Science With 24.66% Discount seekingalpha.com - April 23 at 3:43 PM
	Celgene: Will Tremfya Punish Otezla Too? seekingalpha.com - April 23 at 10:15 AM
	Pre-Market Technical Scan on Biotech Equities -- Cara Therapeutics, Catabasis Pharma, Catalyst Biosciences, and Celgene www.prnewswire.com - April 23 at 7:30 AM
	Celgene (CELG) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - April 22 at 3:30 PM
	CELGENE SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors ... www.businesswire.com - April 21 at 10:09 AM
	EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commencement of a Class ... www.businesswire.com - April 20 at 3:46 PM
	EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG finance.yahoo.com - April 20 at 3:46 PM
	Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Celgene Corporation (CELG) and Encourages Investors to Contact the Firm finance.yahoo.com - April 20 at 10:45 AM
	SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Celgene Corporation (CELG) and Lead Plaintiff Deadline: May 29, 2018 finance.yahoo.com - April 20 at 10:45 AM
	Zacks Investment Research Upgrades Celgene (CELG) to "Hold" www.americanbankingnews.com - April 19 at 11:46 AM
	BRIEF-Celgene Announces Changes To Its Board Of Directors www.reuters.com - April 19 at 10:30 AM
	Celgene (CELG) Announces Board Changes www.streetinsider.com - April 19 at 10:30 AM
	Leerink Swann Analysts Raise Earnings Estimates for Celgene (CELG) www.americanbankingnews.com - April 19 at 7:04 AM
	Celgene (CELG) PT Set at $129.00 by Credit Suisse Group www.americanbankingnews.com - April 18 at 8:41 AM
	Q1 2018 EPS Estimates for Celgene (CELG) Boosted by Leerink Swann www.americanbankingnews.com - April 18 at 7:58 AM
	Celgene (CELG) Scheduled to Post Earnings on Wednesday www.americanbankingnews.com - April 18 at 1:52 AM
	Celgene (CELG) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 17 at 5:54 PM
	Risankizumab Could Be AbbVie’s Long-Term Growth Driver finance.yahoo.com - April 17 at 10:33 AM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action ... globenewswire.com - April 16 at 3:51 PM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Celgene Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018 – CELG finance.yahoo.com - April 16 at 3:51 PM
	Celgene (CELG) PT Set at $134.00 by Mizuho www.americanbankingnews.com - April 15 at 8:22 PM
	Celgene (CELG) Upgraded to "Buy" by Argus www.americanbankingnews.com - April 15 at 9:23 AM
	CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100000 ... globenewswire.com - April 14 at 5:55 PM
	CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG finance.yahoo.com - April 14 at 5:55 PM
	Morgan Stanley Resumes Celgene (CELG) at Equalweight www.streetinsider.com - April 13 at 3:46 PM
	Morgan Stanley Reiterates Equal Weight Rating for Celgene (CELG) www.americanbankingnews.com - April 13 at 11:01 AM
	Analysts Expect Celgene Co. (CELG) Will Announce Quarterly Sales of $3.50 Billion www.americanbankingnews.com - April 13 at 4:41 AM
	Otezla: Shoring Up Celgene’s Top Line finance.yahoo.com - April 12 at 3:49 PM
	The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene Corporation finance.yahoo.com - April 12 at 3:49 PM
	INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead ... www.businesswire.com - April 12 at 11:24 AM
	INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit finance.yahoo.com - April 12 at 11:23 AM
	Celgene (CELG) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 12 at 10:53 AM
	Celgene (CELG) Earns "Outperform" Rating from Oppenheimer www.americanbankingnews.com - April 11 at 10:42 PM
	Novartis Enters Agreement to Acquire AveXis finance.yahoo.com - April 11 at 3:45 PM
	Zacks: Analysts Expect Celgene Co. (CELG) Will Post Earnings of $2.01 Per Share www.americanbankingnews.com - April 11 at 3:14 AM
	Celgene Stock Performance in 1Q18 finance.yahoo.com - April 10 at 3:43 PM
	Agios Pharmaceuticals Shares Rise on Buyout Speculation finance.yahoo.com - April 10 at 3:43 PM
	Celgene (CELG) Lowered to Buy at Vetr www.americanbankingnews.com - April 9 at 8:36 PM
	Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018 www.businesswire.com - April 9 at 10:45 AM
	Celgene hunts deals to offset loss of Revlimid patent protection www.ft.com - April 8 at 3:48 PM
	Hagens Berman Alerts Investors in Celgene Corporation to the May 29, 2018 Lead Plaintiff Deadline in the Pending ... globenewswire.com - April 7 at 5:10 PM
	Celgene (CELG) PT Set at $162.00 by Cantor Fitzgerald www.americanbankingnews.com - April 7 at 11:47 AM
	Sanford C. Bernstein Initiates Coverage on Celgene (CELG) www.americanbankingnews.com - April 6 at 10:54 PM
	JPMorgan Chase Reiterates Buy Rating for Celgene (CELG) www.americanbankingnews.com - April 6 at 10:22 PM
	Celgene (CELG) Upgraded at Vetr www.americanbankingnews.com - April 6 at 12:43 PM
	Celgene (CELG) Price Target Cut to $115.00 www.americanbankingnews.com - April 6 at 12:23 PM
	CELG INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Celgene Corporation ... www.businesswire.com - April 6 at 11:07 AM
	FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene Corporation to Advance a Novel Protein ... www.businesswire.com - April 5 at 3:45 PM
	Glancy Prongay & Murray LLP Continues Investigation on Behalf of Celgene Corporation Investors (CELG) www.businesswire.com - April 5 at 3:45 PM
	Long-Term Celgene (CELG) Investors: Johnson Fistel Investigates Celgene Corporation; Encourages Long-Term Investors to Contact the Firm www.prnewswire.com - April 5 at 2:16 PM

Celgene (NASDAQ:CELG) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Celgene (NASDAQ:CELG) Income Statement, Balance Sheet and Cash Flow Statement

Celgene (NASDAQ CELG) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff